Is Viking Therapeutics (VKTX) Undervalued As Obesity Hopes Meet A Rich P B?
Viking Therapeutics (VKTX) is back on investor calendars after confirming a presentation slot at the 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York on September 11, 2026.
Viking Therapeutics has been volatile into the conference, with the share price down 8.3% over the past week and 3.7% over the last month, yet still posting a 7.9% 90 day share price gain and a 5 year total shareholder return of 378.0%. This indicates that long term momentum remains strong even as traders reassess near term risk around clinical and competitive updates.
Compare Viking Therapeutics with other potential high growth biodeveloped stories by scanning our hand picked list of 15 high quality undiscovered gems moving on clinical and pipeline catalysts.
The recent pullback in Viking Therapeutics after a strong multi year run raises a simple issue: Are you seeing business reality catching up with the hype, or sentiment resetting around the same core story before the next valuation check?
Most Popular Narrative: 74.4% Undervalued
Against a last close of $31.98, the most followed Viking Therapeutics valuation storyline anchors on a fair value of $125. That is a large gap that depends heavily on how obesity trial and commercial execution play out over the next few years.
The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path that may diversify future revenue sources and create operating leverage if both oral and injectable share the same active molecule.
Want to understand why this narrative stretches Viking Therapeutics so far above today’s price? The entire case leans on sizeable future obesity revenue, higher margins, and a valuation multiple more commonly seen in fast growing sectors. Curious which exact assumptions around trial success, earnings power, and discount rate are doing the heavy lifting in that $125 figure? The full breakdown lays it out line by line.
Result: Fair Value of $125.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, this bullish Viking Therapeutics story can crack if VK2735 stumbles in late stage trials or if rising obesity competition squeezes future pricing power.
Find out about the key risks to this Viking Therapeutics narrative.
Another View on Viking Therapeutics Valuation
The bullish $125 fair value story leans on future obesity revenue and earnings, but the market is already paying up on a different yardstick. Viking Therapeutics trades on a P/B of 9.1x, compared with 3.8x for peers and 2.3x for the wider US Biotechs group. This points to a rich valuation that leaves less room for disappointment.
That kind of gap often reflects investors banking on a best case outcome rather than a fair ratio that the share price could move toward if expectations cool. The question is how comfortable you are with paying that much upfront for potential VK2735 success.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling torn between the bullish fair value story and a rich P/B for Viking Therapeutics is normal, especially with clinical milestones still ahead. Move quickly from headline impressions to hard evidence by reviewing the 3 important warning signs.
Looking for more Viking Therapeutics style ideas?
If Viking Therapeutics has your attention, do not stop at a single ticker. Use focused screeners to spot other opportunities before the crowd notices them.
- Target potential mispricings by scanning companies flagged as 32 high quality undervalued stocks that combine solid fundamentals with share prices that lag their underlying metrics.
- Strengthen your income stream by reviewing 6 dividend fortresses that pair higher yields with business profiles designed to support regular payouts.
- Focus on resilience by checking 11 resilient stocks with low risk scores that show lower risk scores and may help balance out more volatile holdings in your portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com